Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes?

Diabetic Medicine

Volumn 14, Issue 9, 1997, Pages 723-731

  Dunger, D B ^a,b   Acerini, C L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GROWTH HORMONE; HEMOGLOBIN A1C; INSULIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DOUBLE BLIND PROCEDURE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROLIFERATIVE RETINOPATHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; RECOMBINANT PROTEINS;

EID: 0030767474     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199709)14:9<723::AID-DIA480>3.0.CO;2-S     Document Type: Review

References (81)

1. Jansen M, Van Schaik FMA, Recker AT, Bullock B, Woods DE, Gabbay KH, Nussbaum AL, Sussenbach JS, Van den Brande JL. Sequence of cDNA encoding human insulin-like growth factor-1 precursor. Nature 1983; 306: 609-611.
2. Guler HP, Zapf J, Schwawiller E, Froesch ER. Recombinant human insulin-like growth factor-1 stimulates growth and has distinct effects on organ size in hypophysectomised rats. Proc Natl Acad Sci 1988; 85: 4889-4893.
3. Skottner A, Clark RG, Robinson ICAT, Fryklund L. Recombinant human insulin-like growth factor: testing the somatomedin hypothesis in hypophysectomised rats. J Endocrinology 1987; 112: 123-132.
4. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Blum WF, Wilten P. Insulin-like growth factor I improves height in growth hormone insensitivity syndrome: two year's results. Horm Res 1995; 44: 235-264.
5. Cotterill AM. The therapeutic potential of recombinant human insulin-like growth factor-1. Clin Endocrinol (Oxf) 1192; 37: 11-16.
6. Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA, Skarculis M. Clinical uses of insulin-like growth factor-1. Annals Int Med 1994; 120: 593-601.
7. Froesch ER, Burgi H, Ramseier EB, Bally P, Labhart A. Antibody-suppressible and non-suppressible insulin-like activities in human serum and their physiologic significance. An insulin assay with adipose tissue of increased precision and specificity. J Clin Invest 1963; 42: 1816-1834.
8. Zapf J, Schoenle E, Froesch ER. Insulin-like growth factors-1 and 11, some biological actions and receptor binding characteristics of two purified constituents of non-suppressible insulin-like activity of human serum. Eur J Biochem 1978; 87: 285-296.
9. Rinderknecht E, Humbel RE. The amino-acid sequence of human insulin-like growth factor 1 and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769-2776.
10. Massague J, Czech MP. The subunit structure of two distinct receptors for insulin-like growth factors 1 and 11 and their relationship to the insulin receptor. J Biol Chem 1982; 257: 5038-5045.
11. Dimitriadis G, Parry-Billings M, Dunger DB, Bevan S, Colquhoun A, Taylor A, et al: Effects of in vivo administration of insulin-like growth factor-1 (IGF-1) on the sensitivity of glucose utilisation to insulin in the soleus muscle of rat. J Endocrinol 1992; 133: 37-43.
12. Dimitriadis G, Parry-Billings M, Piva T, Dunger DB, Bevan S, Wegener G, et al. Effects of insulin like growth factor 1 on the rates of glucose transport and utilisation in rat skeletal muscle in vitro. Biochem J 1992; 285: 269-274.
13. Le Roith D, Sampson PC, Roberts CT. How does the mitogenic insulin-like growth factor-1 receptor differ from the metabolic insulin receptor? Horm Res 1994; 41 (suppl 2): 74-79.
14. Myers MG Jr, Sun XJ, Chatham B, Jachna BR, Glasheen EM, Backer JM, White MF. IRS-1 is a common element of insulin and IGF-1 signalling to the phosphatidylinositol 3′-kinase. Endocrinology 1993; 132: 1421-1430.
15. Lammers R, Gray A, Schlessinger J, Ullrich A. Differential signalling potential of insulin and IGF-1 receptor of cytoplasmic domains. EMBO J 1989; 8: 1369-1375.
16. Ballard FJ, Baxter RC, Binoux M, and participants of the Second International IGF Symposium. Report on the nomenclature of the IGF binding proteins. J Clin Endocrinol Metab 1992; 74: 1215-1216.
17. Binoux M, Hossenlopp P. Insulin-like growth factor (IGF) and IGF-binding proteins: comparison of human serum and lymph. J Clin Endocrinol Metab 1988; 67: 509-514.
18. Guler HP, Zapf J, Schmidt C, Froesch ER. Insulin-like growth factors 1 and 11 in healthy man. Estimation of half-lives and production rates. Acta Endocrinol 1989; 121: 753-758.
19. Clemmons DR. IGF binding proteins: regulations of cellular actions. Growth Regul 1992; 2: 80-87.
20. Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, Binoux M. Evidence of enzymatic degradation of insulin-like growth factor binding proteins in the 150K complex during pregnancy. J Clin Endocrinol Metab 1990; 71: 797-805.
21. Davenport ML, Isley WL, Pucilowska JB, Beatty Pemberton L, Lyman B, Underwood LE, Clemmons DR. Insulin-like growth factor binding protein-3 proteolysis is induced after elective surgery. J Clin Endocrinol Metab 1992; 75: 590-595.
22. Baxter RC, Turtle JR. Regulation of hepatic growth hormone receptors by insulin. Biochem Biophys Res Comm 1978; 84: 350-357.
23. Maes M, Underwood LE, Ketelslegers J-M. Low serum somatomedin-C in insulin-dependent diabetes: evidence for a post receptor mechanism. Endocrinology 1986; 118: 377-382.
24. Leung DW, Spencer SA, Cachianes G, Hammonds G, Collins C, Henzel WJ, et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987; 330: 537-543.
25. Hochberg Z, Hertz P, Colin V, Ish-Shalon S, Youdim MBH, Amil T. The distal axis of growth hormone in nutritional disorders: GH binding protein, insulin like growth factor-1 (IGF-1) and IGF-1 receptors in obesity and anorexia nervosa. Metabolism 1992; 41: 106-112.
26. Cotterill AM, Cowell CJ, Silink M. Insulin and variation in glucose levels modify the secretion rates of growth hormone independent insulin-like growth factor binding protein-1 in the human hepatoblastoma cell line Hep G2. Endocrinology 1989; 123: R17.
27. Holly JMP, Biddlecombe RA, Dunger DB, Edge JA, Amiel SA, Howell R, et al. Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin. A new role for insulin? Clin Endocrinol (Oxf) 1988; 29: 667-675.
28. Taylor AM, Dunger DB, Preece MA, Holly JMP, Smith CP, Wass JAH, et al. The growth hormone independent insulin-like growth factor-1 binding protein BP-28 is associated with serum insulin-like growth factor-1 inhibitory bioactivity in adolescent insulin dependent diabetes. Clin Endocrinol (Oxf) 1990; 32: 229-239.
29. Bereket A, Lang CH, Blethen SL, Fan J, Frost KA, Wilson TA. Insulin-like growth factor binding protein-3 proteolysis in children with insulin dependent diabetes mellitus: a possible role for insulin the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 1995; 80: 2282-2288.
30. Dunger DB. Insulin and insulin-like growth factors in diabetes mellitus. Arch Dis Child 1995; 72: 469-471.
31. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor-1 in healthy adults. N Engl J Med 1987; 317: 137-140.
32. Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS. Diverse effects of insulin-like growth factor 1 on glucose lipid and amino acid metabolism. Am J Physiol 1992; 262: E130-133.
33. Sherwin RS, Borg WP, Boulware SD. Metabolic effects of insulin-like growth factor 1 in normal humans. Horm Res 1994; 41 (suppl 2): 97-102.
34. Lewitt MS, Denyer GS, Cooney GJ, Baxter RC. Insulin-like growth factor binding protein-1 modulates blood glucose levels. Endocrinology 1991; 129: 2254-2256.
35. Bereket A, Lang CH, Blethen SL, Co Ng L, Wilson TA. Insulin treatment normalises reduced free insulin-like growth factor-1 concentrations in diabetic children. Clin Endocrinol 1996; 45: 321-326.
36. Batch JA, Baxter RC, Werther G. Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin-dependent diabetes. J Clin Endocrinol Metab 1991; 73: 964-968.
37. Cotterill AM, Daly F, Holly JMP, Cwyfan-Hughes S, Camacho-Hulner C, Farhana Abdulla A, Gale EAM, Savage MO. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1. Clin Endocrinol 1995; 43: 567-574.
38. Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, Froesch ER. Insulin-like growth factor-1 stimulates lipid oxidation, reduces protein oxidation and enhances insulin sensitivity in humans. J Clin Invest 1993; 92: 2249-2256.
39. Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER. Recombinant human insulin-like growth factor-1 (rhIGF-1) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetalogia 1991; 34: 675-679.
40. Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC. Recombinant human insulin-like growth factor-1 therapy improves glycaemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 1994; 79: 205.
41. Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS. Insulin-like growth factor 1 (rhIGF-1) as a therapeutic agent for hyperinsulinemic insulin resistant diabetes mellitus. Diabetes Res Clin Pract 1995; 28 (suppl): S185-S194.
42. Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, et al. Trial of insulin-like growth factor 1 therapy for patients with extreme insulin resistance syndromes. Diabetes 1993; 42: 696-705.
43. Taylor SI, Cama A, Arcili D, Barbetti F, Imano E, Kadowaki H, Kadowaki T. Genetic basis of endocrine disease. Molecular genetics of insulin resistant diabetes mellitus. J Clin Endocrinol Metab 1991; 73: 1158-1163.
44. Van Obbergen-Schilling EE, Rechler MM, Romanus JA, Knight AB, Nissley SP, Humbel RE. Receptors for insulin-like growth factor 1 are defective in fibroblasts cultured from a patient with leprechaunism. J Clin Invest 1981; 68: 1356-1365.
45. Backeljauw PF, Alves C, Eidson M, Cleveland W, Underwood LE, Davenport ML. Effect of intravenous insulin-like growth factor 1 in two patients with leprechaunism. Paed Res 1994; 36: 749-754.
46. Quinn JD, Fisher BM, Paterson KR, Inoue A, Beastall GH, MacCuish AC. Acute response to recombinant insulin-like growth factor 1 in a patient with Mendenhall's syndrome (Letter). N Engl J Med 1990; 323: 1425-1426.
47. Zenobi PD, Silvia E, Jaeggi-Groisman S, Riesen WF, Roder ME, Froesch ER. Insulin-like growth factor-1 improves glucose and lipid metabolism in Type 2 diabetes mellitus. J Clin Invest 1992; 90: 2234-2241.
48. Schalch DS, Turman NJ, Marcsisin VS, Hefferman M, Guler HP. Short-term effects of recombinant human insulin-like growth factor 1 on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1563-1568.
49. Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS, Radnik BJ, et al. Adverse effects of recombinant human insulin-like growth factor 1 in obese insulin resistant type II diabetic patients. Diabetes 1994; 43: 369-374.
50. Moses AC, Young SCJ, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor 1 increases insulin sensitivity and improves glycaemic control in type II diabetes. Diabetes 1996; 45: 91-100.
51. RINDS. Safety profiling of rhIGF-1 therapy in patients with NIDDM: a doseranging, placebo control trial. Diabetes 1996; 45 (suppl 2): 71A.
52. RINDS. Evidence from a dose-ranging study that recombinant insulin-like growth factor 1 (RhIGF-1) effectively and safely improves glycemic control in non-insulin dependent diabetes mellitus (Abstracts). Diabetes 1996; 45 (suppl 2): 27A.
53. Tann K, Baxter RC. Serum insulin-like growth factor 1 levels in adult diabetic patients: the effect of age. J Clin Endocrinol Metab 1986; 63: 651-655.
54. Taylor AM, Dunger DB, Grant DB, Preece MA. Somatomedin C (IGF-1) measured by radioimmunoassay and somatomedin bioactivity in adolescents with insulin dependent diabetes compared with puberty matched controls. Diabetes Res 1988; 9: 177-181.
55. Arslanian SA, Menon RK, Gierl AP, Heil BV, Foley Jr TP. Insulin therapy increases low plasma growth hormone binding protein in children with new onset Type 1 diabetes. Diabetic Med 1993; 10: 833-836.
56. Menon RK, Arslanian SA, May B, Cutfield WS, Spening MA. Diminished growth hormone-binding protein in children with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1992; 74: 934-938.
57. Massa G, Dooms L, Bouillon R, Vanderschureren-Loceweyckx M. Serum levels of growth hormone-binding protein and insulin-like growth factor 1 in children and adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 239-243.
58. Clayton KL, Holly JMP, Carlsson LMS, Jones J, Cheetham TD, Taylor AM, Dunger DB. Loss of the normal relationships between growth hormone, growth hormone binding protein and insulin-like growth factor-1 in adolescents with insulin dependent diabetes mellitus. Clin Endocrinol (Oxf) 1994; 41: 517-524.
59. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-1 in insulin-dependent diabetes. J Clin Endocrinol Metab 1994; 79: 872-878.
60. Edge JA, Dunger DB, Matthews DR, Gilbert JR, Snith CP. Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab 1990; 71: 1356-1562.
61. Amiel SA, Sherwin RS, Simonson DV, Laumtano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycaemic control in adolescents with diabetes. N Engl J Med 1986; 315: 215-219.
62. Fowelin J, Attvall S, von Schenck H, Smith U, Lager I. Characterisation of the insulin-antagonistic effect of growth hormone in man. Diabetologia 1991; 34: 500-506.
63. Edge JA, Matthews DR, Dunger DB. The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics. Clin Endocrinol 1990; 33: 729-737.
64. Pal BR, Phillips PE, Matthews DR, Dunger DB. Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 542-549.
65. Edge JA, Harris DA, Phillips PE, Pal BR, Dunger DB. Evidence for a role for insulin and growth hormone in the overnight regulation of 3-hydroxybutyrate in normal and diabetic adolescents. Diabetes Care 1993; 16: 1011-1019.
66. Dunger DB. Diabetes in puberty. Arch Dis Child 1992; 67: 569-570.
67. Drash AL. The child, the adolescent, and the diabetes control and complications trial. Diabetes Care 1993; 16: 1515-1516.
68. Cheetham TD, Jones J, Taylor AM, Holly IMP, Matthews DR, Dunger DB. The effects of recombinant insulin-like growth factor-1 administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 678-681.
69. Bach MA, Chin E, Bondy CA. The effects of subcutaneous insulin-like growth factor-1 infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994; 79: 1040-1045.
70. Cheetham TD, Connors M, Clayton K, Watts A, Dunger DB. Insulin sensitivity before and after recombinant human insulin-like growth factor 1 (rhIGF-1) administration in adolescents with IDDM: importance of GH concentrations. Clin Endocrinol 1997; 46: 415-425.
71. Crowne EC, Samra J, Holly JMP, Cheetham TD, Dunger DB. Administration of rhIGF-1 and GH prevents GH-induced changes in insulin sensitivity in IDDM (Abstract). Horm Res 1995; 44: (suppl): 311.
72. Crowne EC, Samra JS, Acerini CL, Cheetham T, Jones J, Holly JMP, Dunger DB. The role of IGFBP-1 in mediating direct effects of rhIGF-1 administration on insulin sensitivity in IDDM (Abstract). Horm Res 1996; 46 (suppl): 257.
73. Cheetham TD, Holly JMP, Clayton K, Curfan-Hughes S, Dunger DB. The effects of repeated daily recombinant human insulin-like growth factor 1 administration in adolescents with Type 1 diabetes. Diabetic Med 1995; 12: 885-892.
74. Quattrin T, Thrailkill K, Baker L, Litton J, Dwigun K, Rearson M, et al. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor 1 in IDDM. Effects on glycaemic control, IGF-1 levels, and safety profile. Diabetes Care 1997; 20: 374-380.
75. Acerini CL, Patton CM, Kernell A, Savage MO, Westphal O, Dunger DB. A trial of insulin-like growth factor-1 as an adjunct to multiple injection therapy in insulin dependent diabetes (Abstract). Diabetologia 1997; 40 (suppl 1): A330.
76. Burger W, Hövener, Düsterhus R, Hartmann R, Wever B. Prevalance and development of retinopathy in children and adolescents with Type 1 (insulin-dependent) diabetes mellitus. A longitudinal study. Diabetologia 1986; 29: 17-22.
77. Dills DG, Moss SE, Klein R, Klein BEK, Davis M. Is insulin-like growth factor 1 associated with diabetic retinopathy? Diabetes 1990; 39: 191-195.
78. Dills DG, Moss SE, Klein R, Klein BEK. Association of elevated IGF-1 levels with increased retinopathy in late-onset diabetes. Diabetes 1991; 40: 1725-30.
79. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N Eng J Med 1983; 309: 527-530.
80. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufriekha M, Guy J. Insulin-like growth factor 1 acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 1993; 36: 282-291.
81. Gerich JE. Role of growth hormone in diabetes mellitus. N Engl J Med 1984; 310: 848-850.